[ad_1]
BRUSSELS: The leader of European Unionmedical agency Guido Rasi on Monday said a first permit for the U.S. pharmaceutical company Gilead‘s remdesivir then to Treatment of covid-19 could be awarded in the coming days.
That European Medicines Agency (EMA) has already recommended compassionate use of remdesivir, which allows a drug to be administered to patients even before it is fully approved.
“A conditional marketing authorization could be issued in the coming days,” Rasi told a hearing in the European Parliament in Brussels.
Apart from remdesivir, Rasi said other possible treatments against COVID-19 that may be readily available are those based on monoclonal antibodies that can “neutralize” the new coronavirus (SARS-CoV-2) that causes COVID-19 disease.
[ad_2]
Source link